Table 3 Overview of published ApoC1 serum levels.
From: Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study
ApoC1 serum levels in different populations | ||||
|---|---|---|---|---|
Year | Author | Population | Patients | Level [µg/ml] |
1981 | Curry et al7 | Control | n.d | 60.0 |
Hyperlipoproteinemia | n.d | 132.5 | ||
1982 | Carlson and Holmquist8 | Normolipidemic men | 29 | 63.0 |
1986 | Riesen and Sturzenegger9 | Apparently healthy males | 38 | 61.0 |
Apparently healthy females | 32 | 65.0 | ||
1987 | Attman et al10 | Control | 42 | 85.5 |
Chronic renal failure | 33 | 93.0 | ||
1993 | Bren et al11 | control | 26 | 72.0 |
Diabetes | 14 | 113.2 | ||
Type V hyperlipoproteinemia | 12 | 137.8 | ||
2003 | Cohn et al12 | Normolipidemic | 89 | 105.7 |
Hyperlipidemic | 88 | 128.7 | ||
2005 | Shachter et al13 | Hispanic children | 362 | 62.0 |
2007 | Dautin et al14 | Chronic renal failure | 28 | 131.1 |
2008 | Berbée et al15 | Sepsis | 17 | 13.4 |
2010 | Lahiry16 | Male Oji-Cree | 192 | 220.7 |
Female Oji-Cree | 217 | 203.9 | ||
Xue et al17 | Control | 18 | 107,000.0 | |
Pancreatico-biliary pathology | 28 | 101,000.0 | ||
2011 | Cohen et al18 | Control | 54 | 92.5 |
2013 | McNeal et al19 | Vascular | 20 | 115.4 |
2014 | Ko et al20 | Control | 8 | 50.0 |
Pneumonia | 16 | 50.0 | ||
2018 | Al-Daghri et al21 | Vitamin D substitution | 120 | 35.2 |
Dittrich et al22 | control | 1300 | 40.0 | |
2019 | Wang et al23 | Control | 60 | 17,390.0 |
Chronic atrophic gastritis | 60 | 12,830.0 | ||
Yi et al24 | Control | 40 | 0.1 | |
Non-tumor patients | Number | 2943 | ||
Mean | 8584.0 | |||
Median | 92.8 | |||
2010 | Xue et al17 | Pancreatic adenocarcinoma | 33 | 124,000.0 |
2011 | Cohen et al18 | Stomach cancer | 101 | 31.3 |
2014 | Ko et al20 | Lung cancer | 48 | 50.0 |
2019 | Wang et al23 | Gastric cancer | 60 | 9530.0 |
Yi et al24 | Gastric cancer | 65 | 0.3 | |
Present study | glioblastoma | 68 | 91.9 | |
Tumor patients | Number | 375 | ||
Mean | 22,283.9 | |||
Median | 71.0 |
